Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|October 10, 2019

Rapid Low-level Identification and Quantitation of Host Cell Proteins

Do you need an automated and streamlined method for identification and characterization of host cell protein (HCP) impurities? Learn how to optimize each stage of your HCP workflow by attending this webcast. Live: Europe: Thursday, Oct. 10, 2019 at 2pm BST | 3pm CEST North America: Thursday, Oct. 10, 2019 2pm EDT | 1pm CDT | 11am PDT On demand available after final airing until Oct. 10, 2020 Register free

Register free: http://www.biopharminternational.com/bp_w/proteins

Event Overview:

Process impurities such as host cell proteins (HCPs) can threaten product efficacy and stability and, therefore, must be monitored and controlled in drug products. 

The traditional enzyme-linked immunosorbent assay (ELISA) method lacks the specificity and coverage to identify and quantify individual HCPs. Liquid chromatography (LC)–mass spectrometry (MS) analysis overcomes that these limitations; however, the coelution of low-abundance HCP peptides with the highly abundant peptides from the drug product demands better separation of the peptides and broad dynamic range of the LC/MS system.

In this webcast, experts will review an HCP analysis workflow for automated sample preparation; an LC–MS/MS analysis using a new acquisition method shown to improve protein identification; and data analysis software to confirm identification of HCPs.

Key Learning Objectives:

How to optimize each stage of a host cell protein workflow including sample prep, separation, detection, and data processing

How a new acquisition method can identify lower-level peptides

How to perform targeted quantitation of HCPs

Speakers: Steve Madden, Software Product Manager, Agilent Technologies

Linfeng Wu, PhD, Application Scientist, Agilent Technologies

Time and Date: Europe: Thursday, October 10, 2019 at 2pm BST | 3pm CEST

North America: Thursday, October 10, 2019 2pm EDT | 1pm CDT | 11am PDT

On demand available after final airing until Oct. 10, 2020

Sponsor: Agilent Technologies

Register free: http://www.biopharminternational.com/bp_w/proteins


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.